Clinical trials: Decompensated Liver Cirrhosis
Decompensated Cirrhosis
Hospital @ Home Model of Care for Cirrhosis
The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and…
- Trial name
- H@H (NCT06396897)
- Testing
- Indiana University Health Hospital at Home Program
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores.
- Trial name
- NCT07002827
- Testing
- Darbepoetin, G-CSF, Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
This study is a companion protocol that will use the data generated by Conatus' study of emricasan under protocol IDN-6556-17.The IDN-6556-17 study is a Phase 2, multicenter, double-blind, placebo-controlled trial of Emricasan in…
- Trial name
- NCT03462576
- Testing
- Methacetin Breath Test, Emricasan
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Meridian Bioscience, Inc.
End-stage Liver Disease (ESLD), Cirrhosis, Liver
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and…
- Conditions
- End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases
- Trial name
- EMERALD (NCT06823713)
- Testing
- RTX001
- Where
- 15 sites in Spain, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Resolution Therapeutics Limited
Liver Cirrhoses
Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of…
- Trial name
- 2018-001698-25 (NCT03780673)
- Testing
- Simvastatin, Rifaximin
- Where
- 14 sites in Belgium, France and 5 more
- Volunteers
- 254 people
- Sponsor
- Judit Pich
Decompensated Cirrhosis
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)
This clinical trial is a Phase 1, multiple administration, dose-escalasion clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis.
- Trial name
- NCT05984303
- Testing
- Human Umbilical Cord-derived Mesenchymal Stem Cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing 302 Hospital
Decompensated Cirrhosis, CMV Reactivation
Prospective Cohort Study of Complications and Outcomes in Cirrhosis
This is a multi-center, nested cohort study intended to investigate the prevalence, risk factors, and outcomes of complications in patients with acutely decompensated cirrhosis, especially focused on Cytomegalovirus (CMV)…
- Conditions
- Decompensated Cirrhosis, CMV Reactivation, Overt Hepatic Encephalopathy
- Trial name
- NCT06374511
- Testing
- Test for CMV reactivation
- Where
- China
- Volunteers
- 660 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Decompensated Cirrhosis and Ascites
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in participants…
- Trial name
- PRECIOSA (NCT03451292)
- Testing
- Albutein 20%, SMT
- Where
- 66 sites in United States, Belgium and 12 more
- Volunteers
- 410 people
- Sponsor
- Grifols Therapeutics LLC
Cirrhosis, Liver, Rectal Colonization
Longitudinal Surveillance of Rectal Colonization and Transmission by Resistant Bacteria in Acutely Decompensated Cirrhosis
Antimicrobial resistance has emerged as a global threat, and multidrug resistance organisms (MDROs) form one of the foremost challenges in the setting of decompensated cirrhosis.
- Conditions
- Cirrhosis, Liver, Rectal Colonization, Multidrug Resistance Organisms
- Trial name
- NCT06511492
- Testing
- No intervention in this study
- Volunteers
- 1,289 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cirrhosis, Liver
G-CSF in Decompensated Cirrhosis: an Open Label Trial
Globally, cirrhosis is the fifth commonest cause of mortality. Its natural history is typified by an initial, largely asymptomatic, "compensated" phase followed by "decompensation" due to complications of raised portal pressures…
- Trial name
- NCT03415698
- Testing
- G-CSF, Standard Medical Therapy
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cirrhosis
To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.
The study will be conducted on patients admitted to Department of Hepatology from MARCH 2015 to DECEMBER 2016 at ILBS, New Delhi.All patients presenting to ILBS fulfilling the inclusion criteria will be included in the study and…
- Trial name
- NCT02465619
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Acute Decompensation
Study of microRNAs in a Decompensated Cirrhosis
Cirrhotic patients are at higher risk of sepsis due to impaired innate and adaptive immune responses. Septic complications represent a major issue in the management of cirrhotic patients, with a 1-month mortality rate of 23%…
- Trial name
- EmiC (NCT03905746)
- Testing
- blood sample at Day 0, blood sample at Day 2 and Day 7, stool sample at Day 0
- Where
- France
- Volunteers
- 444 people
- Sponsor
- Hospices Civils de Lyon
Cirrhosis
Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis
The standard treatment for decompensated cirrhosis is liver transplantation, however, it has several limitations. Recent animal studies suggest that bone marrow stem cell transplantation can lead to regression of liver fibrosis.
- Trial name
- NCT00476060
- Testing
- Autologous mesenchymal stem cell transplantation
- Where
- Iran
- Volunteers
- 27 people
- Sponsor
- University of Tehran
Ascites, Decompensated Cirrhosis
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of ascites and complications in adult patients…
- Trial name
- NCT04112199
- Testing
- BIV201 continuous infusion
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- BioVie Inc.
Cirrhosis Due to Hepatitis B
A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the literature about there effectiveness in HBV…
- Trial name
- NCT02238860
- Testing
- Entacavir, Tenofovir
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Asian Institute Of Medical Sciences
Stem Cell Transplantation, Cirrhosis
Autologous Bone Marrow Stem Cells in Cirrhosis Patients
Liver cirrhosis (LC) is the end stage of chronic liver disease. The liver transplantation is one of the only effective therapies available to such patients.
- Trial name
- NCT00713934
- Testing
- CD133, BM-MNC
- Where
- 2 sites in Iran
- Volunteers
- 7 people
- Sponsor
- Royan Institute
Cirrhosis
Study Of Bacterial/Fungal Infections in Hospitalized Patients With Liver Cirrhosis in China
This is a national, investigator-initiated, multicenter, prospective, observational, web-based registry in hospitalized patients with cirrhosis across China.
- Trial name
- SONIC (NCT03676777)
- Where
- 23 sites in China
- Volunteers
- 1,232 people
- Sponsor
- Ruijin Hospital
Paracentesis-Induced Circulatory Dysfunction
Low-dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis (LVP) in Decompensated Cirrhosis Liver.
Abstract for thesis protocol. Background: Paracentesis induced circulatory dysfunction (PICD) is a common complication of large volume paracentesis in cirrhotic patients, which can lead to renal impairment, hyponatremia, and…
- Trial name
- PICD LVP (NCT06892535)
- Testing
- Albumin infusion, 2g/L of ascitic fluid aspiration.
- Where
- Bangladesh
- Volunteers
- 52 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Decompensated Cirrhosis, Portal Hypertension
TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding
The purpose of this study is to determine whether transjugular intrahepatic portosystemic shunt (TIPS) with 10-mm covered stent is associated with lower shunt dysfunction in comparing TIPS with 8-mm covered stent in cirrhotic…
- Conditions
- Decompensated Cirrhosis, Portal Hypertension, Bleeding Varices
- Trial name
- T8/10SVB (NCT01410591)
- Testing
- 8-mm covered stent group, 10-mm covered stent group
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Air Force Military Medical University, China
Decompensated Hepatitis B Cirrhosis
Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
This study aims to conduct a prospective, multicenter, double-blind, randomized, placebo-controlled trial. The planned sample size is 432 patients, with the ratio of the Fuzheng Huayu group to the placebo control group being 1:1.
- Trial name
- FZHYRORDFDHBLC (NCT07017426)
- Testing
- Fuzheng Huayu tablets
- Volunteers
- 432 people
- Sponsor
- Zhiyun Yang